Pure Drug Safety Ltd
Statement of financial position
as at 31 July 2024
Cash at bank and in hand
(4,894)
(2,472)
Creditors: amounts falling due within one year
(19,056)
(36,556)
Net current liabilities
(19,731)
(35,323)
Total assets less current liabilities
(19,267)
(34,627)
Creditors: amounts falling due after more than one year
(31,507)
(31,587)
Net liabilities
(50,774)
(66,214)
Called up share capital
250
250
Profit and loss account
(51,024)
(66,464)
Shareholders' funds
(50,774)
(66,214)
For the year ending 31 July 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 12 May 2025 and were signed on its behalf by
Carol Kingstone
Director
Company Registration No. 07702236
Pure Drug Safety Ltd
Notes to the Accounts
for the year ended 31 July 2024
Pure Drug Safety Ltd is a private company, limited by shares, registered in England and Wales, registration number 07702236. The registered office is Biocity, Pennyfoot Street, Nottingham, England, NG1 1GF.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation had been based on a 33% reducing balance but this policy has been changed to to the following annual rates n order to write off each asset over its estimated useful life
4
Tangible fixed assets
Plant & machinery
Fixtures & fittings
Total
Cost or valuation
At cost
At cost
At 1 August 2023
35,884
3,599
39,483
At 31 July 2024
36,813
2,914
39,727
At 1 August 2023
35,884
2,903
38,787
Charge for the year
464
244
708
Surplus on revaluation
-
(232)
(232)
At 31 July 2024
36,348
2,915
39,263
At 31 July 2024
465
(1)
464
Pure Drug Safety Ltd
Notes to the Accounts
for the year ended 31 July 2024
Amounts falling due within one year
6
Creditors: amounts falling due within one year
2024
2023
Bank loans and overdrafts
-
4,596
Trade creditors
16,413
14,734
Taxes and social security
479
1,018
Loans from directors
2,156
14,959
7
Creditors: amounts falling due after more than one year
2024
2023
8
Average number of employees
During the year the average number of employees was 1 (2023: 1).